Table 1 Baseline characteristics and outcome
Characteristics | Non-survival (n = 121) | Survival (n = 692) | P value |
|---|---|---|---|
Demographic variables | |||
 Male, n (%) | 69 (57.02) | 376 (54.34) | 0.584 |
 Age (years), median (IQR) | 65 (52–76) | 55 (43.5–67) | < 0.001 |
Preexisting clinical conditions | |||
 Hypertension, n (%) | 48 (39.67) | 200 (28.90) | 0.015 |
 COPD, n (%) | 12 (9.92) | 23 (3.32) | 0.002 |
 Coronary disease, n (%) | 28 (23.14) | 54 (7.80) | < 0.001 |
 Diabetes mellitus, n (%) | 25 (20.66) | 86 (12.43) | 0.016 |
 Malignant tumor, n (%) | 23 (18.85) | 128 (18.50) | 0.894 |
 Chronic heart failure, n (%) | 10 (8.26) | 22 (3.18) | 0.011 |
 Chronic liver disease, n (%) | 4 (3.31) | 25 (3.61) | 0.867 |
 Charlson score, median (IQR) | 2 (1–3) | 2 (1–2) | 0.089 |
Source of Admission | |||
 Surgery, n (%) | 58 (47.93) | 522 (75.43) | < 0.001 |
 Internal medicine, n (%) | 30 (24.79) | 44 (6.36) | 0.002 |
 Emergency, n (%) | 34 (28.10) | 127 (18.35) | < 0.001 |
Treatment | |||
 Mechanical ventilation, n (%) | 97 (80.17) | 465 (67.20) | 0.005 |
 RRT, n (%) | 28 (23.14) | 37 (5.35) | < 0.001 |
 Use of corticosteroid, n (%) | 32 (26.45) | 148 (21.39) | 0.217 |
 Use of norepinephrine, n (%) | 63 (51.64) | 78 (11.40) | < 0.001 |
Inflammatory biomarkers, median (IQR) | |||
 PCT (μg/L) | 0.97 (0.23–5.51) | 0.12 (0–1.02) | < 0.001 |
 CRP (mg/L) | 66.70 (12.80–140.00) | 11.95 (2.25–56.15) | < 0.001 |
 WBC (× 109/L) | 13.420 (9.070–17.810) | 11.765 (8.395–15.645) | 0.017 |
 APACHEIIscore, median (IQR) | 23 (18–29) | 14 (9–19) | < 0.001 |
 SOFA score, median (IQR) | 8 (5–11) | 2 (0–5) | < 0.001 |
 Sepsis, n (%) | 82 (67.77) | 223 (32.23) | < 0.001 |
Outcome | |||
 LOS of ICU (days), median (IQR) | 6 (3–12) | 3 (2–8) | < 0.001 |